Business context and reporting period
China SXT Pharmaceuticals, Inc. filed this Form 6-K for October 2026 to report a registered direct offering. The offering closed on October 9, 2026. This filing reports a financing transaction, not quarterly or annual operating results.
Offering and key financial terms
- The Company issued 8,000,000 units at $1.50 per unit, for expected gross proceeds of approximately $12.0 million, before fees and expenses. The filing does not state final net proceeds.
- Each unit includes one Class A ordinary share or, in lieu of a share, one pre-funded warrant to purchase a share, and one ordinary warrant.
- Ordinary warrants have an initial exercise price of $2.75 per share and are exercisable from issuance through the first anniversary of issuance. They permit cashless exercise in specified circumstances and include a zero-exercise-price option; the filing states that up to 72,000,000 Class A ordinary shares may be issuable in aggregate under all warrants, subject to their terms.
- Investors have a 30-day post-closing option to purchase up to an additional $12.0 million of securities on the same terms.
- The placement agent, Univest Securities, LLC, is entitled to a 7.0% cash fee on gross proceeds, plus specified expense reimbursements capped at $50,000.
Material changes and financial condition
The transaction raises capital through share or pre-funded-warrant issuance and accompanying warrants, creating potential dilution. The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or prior-period comparative figures; it does not establish the Company’s overall financial condition.
Outlook, risks, and unusual terms
The filing gives no operating guidance or management outlook. Proceeds from future warrant exercises are not included in the stated expected gross proceeds. The additional purchase right and the warrants’ cashless and zero-exercise-price provisions are material terms that may affect future financing and share count. The filing refers readers to the transaction agreements and warrant forms for complete terms.
Important facts for investors to verify
- Actual closing proceeds, deductions, and net cash received.
- Whether investors exercise the 30-day option for up to $12.0 million of additional securities.
- The number and type of securities issued, including any pre-funded warrants, and the resulting dilution.
- The detailed conditions and potential share impact of the warrants’ cashless and zero-exercise-price provisions.
- The full terms in Exhibits 4.1, 4.2, 10.1, and 10.2.